The Clinical Significance in Healthy Men of the Association Between Obesity Related Plasma Hemodilution and Tumor Marker Concentration

Journal of Urology

Volumn 181, Issue 2, 2009, Pages 567-573

  Chang, In Ho ^a   Ahn, Seung Hyun ^b   Han, June Hyun ^b   Kim, Tae Hyoung ^a   Kim, Young Sun ^a   Myung, Soon Chul ^a  

^a Chung Ang University College of Medicine   (South Korea)

^b Korea Electric Power Research Institute (KEPRI)   (South Korea)

Author keywords

biological; body mass index; hemodilution; obesity; prostatic neoplasms; tumor markers

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CREATININE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; CANCER SCREENING; CLINICAL EXAMINATION; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; HEMODILUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NORMAL HUMAN; OBESITY; ONSET AGE; PLASMA VOLUME; PRIORITY JOURNAL; WEIGHT GAIN;

ADULT; ALPHA-FETOPROTEINS; ANALYSIS OF VARIANCE; BLOOD VOLUME; BODY MASS INDEX; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COHORT STUDIES; EARLY DETECTION OF CANCER; HEMODILUTION; HUMANS; LINEAR MODELS; MALE; MASS SCREENING; MULTIVARIATE ANALYSIS; OBESITY; PROSTATE-SPECIFIC ANTIGEN; REFERENCE VALUES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 58149189823     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.10.030     Document Type: Article

References (19)

1. Pu Y.S., Chiang H.S., Lin C.C., Huang C.Y., Huang K.H., and Chen J. Changing trends of prostate cancer in Asia. Aging Male 7 (2004) 120
2. Bosland M.C., Oakley-Girvan I., and Whittemore A.S. Dietary fat, calories, and prostate cancer risk. J Natl Cancer Inst 91 (1999) 489
3. Andersson S.O., Wolk A., Bergstrom R., Adami H.O., Engholm G., Englund A., et al. Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst 89 (1997) 385
4. Calle E.E., Rodriguez C., Walker-Thurmond K., and Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348 (2003) 1625
5. Chang I.H., Han J.H., and Ahn S.H. Association of obesity with prostate specific antigen and prostate specific antigen velocity in healthy young men. J Urol 179 (2008) 886
6. Baillargeon J., Pollock B.H., Kristal A.R., Bradshaw P., Hernandez J., Basler J., et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 103 (2005) 1092
7. Kristal A.R., Chi C., Tangen C.M., Goodman P.J., Etzioni R., and Thompson I.M. Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer 106 (2006) 320
8. Banez L.L., Hamilton R.J., Partin A.W., Vollmer R.T., Sun L., Rodriguez C., et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 298 (2007) 2275
9. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363 (2004) 157
10. Connolly D., Black A., Murray L.J., Napolitano G., Gavin A., and Keane P.F. Methods of calculating prostate-specific antigen velocity. Eur Urol 52 (2007) 1044
11. Barqawi A.B., Golden B.K., O'Donnell C., Brawer M.K., and Crawford E.D. Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. Urology 65 (2005) 708
12. Werny D.M., Thompson T., Saraiya M., Freedman D., Kottiri B.J., German R.R., et al. Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001-2004. Cancer Epidemiol Biomarkers Prev 16 (2007) 70
13. Farnsworth W.E. Estrogen in the etiopathogenesis of BPH. Prostate 41 (1999) 263
14. Janssen I., Heymsfield S.B., Allison D.B., Kotler D.P., and Ross R. Body mass index and waist circumference independently contribute to the prediction of nonabdominal, abdominal subcutaneous, and visceral fat. Am J Clin Nutr 75 (2002) 683
15. Marin P., and Arver S. Androgens and abdominal obesity. Baillieres Clin Endocrinol Metab 12 (1998) 441
16. Lye W.C., Tambyah P., Leong S.O., and Lee E.J. Serum tumor markers in patients on dialysis and kidney transplantation. Adv Perit Dial 10 (1994) 109
17. Wolff J.M., Ting O., Borchers H., Rohde D., and Jakse G. Serum levels of prostate specific antigen in men on hemodialysis. Anticancer Res 20 (2000) 5191
18. Duvnjak M., Lerotic I., Barsic N., Tomasic V., Virovic Jukic L., and Velagic V. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol 13 (2007) 4539
19. Lee J.Y., Kim K.M., Lee S.G., Yu E., Lim Y.S., Lee H.C., et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol 47 (2007) 239